- Home
- STUB vs GRFS Comparison
STUB vs GRFS Comparison
Compare STUB & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STUB
- GRFS
- Stock Information
- Founded
- STUB 2000
- GRFS 1940
- Country
- STUB United States
- GRFS Spain
- Employees
- STUB N/A
- GRFS N/A
- Industry
- STUB Services-Misc. Amusement & Recreation
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- STUB Consumer Discretionary
- GRFS Health Care
- Exchange
- STUB Nasdaq
- GRFS Nasdaq
- Market Cap
- STUB 6.4B
- GRFS 5.9B
- IPO Year
- STUB 2025
- GRFS 2006
- Fundamental
- Price
- STUB $10.52
- GRFS $8.48
- Analyst Decision
- STUB Buy
- GRFS Hold
- Analyst Count
- STUB 11
- GRFS 1
- Target Price
- STUB $25.00
- GRFS $10.30
- AVG Volume (30 Days)
- STUB 4.0M
- GRFS 782.7K
- Earning Date
- STUB 11-13-2025
- GRFS 01-01-0001
- Dividend Yield
- STUB N/A
- GRFS 1.69%
- EPS Growth
- STUB N/A
- GRFS N/A
- EPS
- STUB N/A
- GRFS 0.64
- Revenue
- STUB $1,829,430,000.00
- GRFS $8,821,017,248.00
- Revenue This Year
- STUB $3.01
- GRFS $5.31
- Revenue Next Year
- STUB $55.81
- GRFS $6.02
- P/E Ratio
- STUB N/A
- GRFS $16.37
- Revenue Growth
- STUB 11.41
- GRFS 7.31
- 52 Week Low
- STUB $10.30
- GRFS $6.19
- 52 Week High
- STUB $27.89
- GRFS $11.14
- Technical
- Relative Strength Index (RSI)
- STUB N/A
- GRFS 33.75
- Support Level
- STUB N/A
- GRFS $8.33
- Resistance Level
- STUB N/A
- GRFS $8.94
- Average True Range (ATR)
- STUB 0.00
- GRFS 0.32
- MACD
- STUB 0.00
- GRFS -0.01
- Stochastic Oscillator
- STUB 0.00
- GRFS 14.50
About STUB StubHub Holdings Inc. Class A Common Stock
Stubhub Holdings Inc is an online marketplace for secondary ticket buy and selling.
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.